Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rosa Dea Sperhacke is active.

Publication


Featured researches published by Rosa Dea Sperhacke.


BMC Infectious Diseases | 2009

Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis

Luciene Cardoso Scherer; Rosa Dea Sperhacke; Antonio Ruffino-Netto; Maria Lucia Rosa Rossetti; Claudia Vater; Paul R. Klatser; Afranio Lineu Kritski

BackgroundTuberculosis is one of the most prominent health problems in the world, causing 1.75 million deaths each year. Rapid clinical diagnosis is important in patients who have co-morbidities such as Human Immunodeficiency Virus (HIV) infection. Direct microscopy has low sensitivity and culture takes 3 to 6 weeks [1–3]. Therefore, new tools for TB diagnosis are necessary, especially in health settings with a high prevalence of HIV/TB co-infection.MethodsIn a public reference TB/HIV hospital in Brazil, we compared the cost-effectiveness of diagnostic strategies for diagnosis of pulmonary TB: Acid fast bacilli smear microscopy by Ziehl-Neelsen staining (AFB smear) plus culture and AFB smear plus colorimetric test (PCR dot-blot).From May 2003 to May 2004, sputum was collected consecutively from PTB suspects attending the Parthenon Reference Hospital. Sputum samples were examined by AFB smear, culture, and PCR dot-blot. The gold standard was a positive culture combined with the definition of clinical PTB. Cost analysis included health services and patient costs.ResultsThe AFB smear plus PCR dot-blot require the lowest laboratory investment for equipment (US


BMC Public Health | 2007

PCR colorimetric dot-blot assay and clinical pretest probability for diagnosis of Pulmonary Tuberculosis in smear-negative patients.

Luciene Cardoso Scherer; Rosa Dea Sperhacke; Carla Jarczewski; Patrícia Izquierdo Cafrune; Simone Minghelli; Marta Osório Ribeiro; Fernanda Cq Mello; Antonio Ruffino-Netto; Maria Lr Rossetti; Afrânio Lineu Kritski

20,000). The total screening costs are 3.8 times for AFB smear plus culture versus for AFB smear plus PCR dot blot costs (US


Journal of Virological Methods | 2011

Evaluation of a novel microplate colorimetric hybridization genotyping assay for human papillomavirus

Regina Bones Barcellos; Sabrina Esteves de Matos Almeida; Rosa Dea Sperhacke; Franciele Rosso; Rúbia Marília de Medeiros; Paulo Fernando Perizzolo; Elizabeth Cortez-Herrera; Maria Lucia Rosa Rossetti

5,635,760 versus US


BMC Pulmonary Medicine | 2011

Comparison of two laboratory-developed PCR methods for the diagnosis of Pulmonary Tuberculosis in Brazilian patients with and without HIV infection

Luciene Cardoso Scherer; Rosa Dea Sperhacke; Carla Jarczewski; Patrícia Izquierdo Cafrune; Candice Tosi Michelon; Rubia Rupenthal; Marta Osório Ribeiro; Antonio Ruffino Netto; Maria Lr Rossetti; Afrânio Lineu Kritski

1,498, 660). Costs per correctly diagnosed case were US


Brazilian Archives of Biology and Technology | 2008

Internal control in PCR for Mycobacterium tuberculosis: usefulness and improvement of the diagnosis

Elizabeth Cortez-Herrera; Rosa Dea Sperhacke; Daniela Becker; Afrânio Lineu Kritski; Arnaldo Zaha; Maria Lucia Rosa Rossetti

50,773 and US


Infectious Disease Reports | 2011

Usefulness of the polymerase chain reaction dot-blot assay, used with Ziehl-Neelsen staining, for the rapid and convenient diagnosis of pulmonary tuberculosis in human immunodeficiency virus-seropositive and -seronegative individuals.

Luciene Cardoso Scherer; Rosa Dea Sperhacke; Maria Lucia Rosa Rossetti; Antonio Ruffino-Netto; Afrânio Lineu Kritski

13,749 for AFB smear plus culture and AFB smear plus PCR dot-blot, respectively. AFB smear plus PCR dot-blot was more cost-effective than AFB smear plus culture, when the cost of treating all correctly diagnosed cases was considered. The cost of returning patients, which are not treated due to a negative result, to the health service, was higher in AFB smear plus culture than for AFB smear plus PCR dot-blot, US


Virus Research | 2006

Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil

Rosangela Rodrigues; Luciene Cardoso Scherer; Cristina M. Oliveira; Heitor Moreira Franco; Rosa Dea Sperhacke; João Leandro de Paula Ferreira; Simone Martins Castro; Isete Maria Stella; Luis Fernando de Macedo Brigido

374,778,045 and US


Chest | 2004

Diagnosing Pleural Tuberculosis

Anete Trajman; Morrys C. Kaisermann; Afranio L. Kritski; Rosa Dea Sperhacke; Maria Lucia Rosa Rossetti

110,849,055, respectively.ConclusionAFB smear associated with PCR dot-blot associated has the potential to be a cost-effective tool in the fight against PTB for patients attended in the TB/HIV reference hospital.


Archive | 2011

Identificação de tuberculose pleural através de PCR em tempo real

Karen Barros Schmid; Franciele Rosso; Candice Tosi Michelon; Rosa Dea Sperhacke; Tatiana Schäffer Gregianini; Liliane Olival; Marcus Barreto Conde; Alexandre Prehn Zavascki; Renata Leborato Guerra; Arnaldo Zaha; Maria Lucia Rosa Rossetti

BackgroundSmear-negative pulmonary tuberculosis (SNPTB) accounts for 30% of Pulmonary Tuberculosis (PTB) cases reported annually in developing nations. Polymerase chain reaction (PCR) may provide an alternative for the rapid detection of Mycobacterium tuberculosis (MTB); however little data are available regarding the clinical utility of PCR in SNPTB, in a setting with a high burden of TB/HIV co-infection.MethodsTo evaluate the performance of the PCR dot-blot in parallel with pretest probability (Clinical Suspicion) in patients suspected of having SNPTB, a prospective study of 213 individuals with clinical and radiological suspicion of SNPTB was carried out from May 2003 to May 2004, in a TB/HIV reference hospital. Respiratory specialists estimated the pretest probability of active disease into high, intermediate, low categories. Expectorated sputum was examined by direct microscopy (Ziehl-Neelsen staining), culture (Lowenstein Jensen) and PCR dot-blot. Gold standard was based on culture positivity combined with the clinical definition of PTB.ResultsIn smear-negative and HIV subjects, active PTB was diagnosed in 28.4% (43/151) and 42.2% (19/45), respectively. In the high, intermediate and low pretest probability categories active PTB was diagnosed in 67.4% (31/46), 24% (6/25), 7.5% (6/80), respectively. PCR had sensitivity of 65% (CI 95%: 50%–78%) and specificity of 83% (CI 95%: 75%–89%). There was no difference in the sensitivity of PCR in relation to HIV status. PCR sensitivity and specificity among non-previously TB treated and those treated in the past were, respectively: 69%, 43%, 85% and 80%. The high pretest probability, when used as a diagnostic test, had sensitivity of 72% (CI 95%:57%–84%) and specificity of 86% (CI 95%:78%–92%). Using the PCR dot-blot in parallel with high pretest probability as a diagnostic test, sensitivity, specificity, positive and negative predictive values were: 90%, 71%, 75%, and 88%, respectively. Among non-previously TB treated and HIV subjects, this approach had sensitivity, specificity, positive and negative predictive values of 91%, 79%, 81%, 90%, and 90%, 65%, 72%, 88%, respectively.ConclusionPCR dot-blot associated with a high clinical suspicion may provide an important contribution to the diagnosis of SNPTB mainly in patients that have not been previously treated attended at a TB/HIV reference hospital.


Archive | 2009

Método de detecção de Mycobacterium tuberculosis e kit de diagnóstico de tuberculose

Maria Lucia Rosa Rossetti; Arnaldo Zaha; Rosa Dea Sperhacke; Leonides Rezende Junior

Persistent infection with high-risk human papillomavirus (HR-HPV) has been associated with cervical cancer. Developing assays for the identification of these viral types is of great importance for monitoring patients and controlling strategies. The development of the MCHA (microplate colorimetric hybridization assay), a PCR-based method for identifying six of the most common HR-HPV types (HPV 16, 18, 31, 33, 39 and 45) is described. The MCHA combines the amplification with the GP5+/GP6+ consensus primers followed by PCR reverse hybridization with specific probes and detection through a colorimetric assay. The performance of the MCHA was evaluated using 108 DNA samples typed previously by the PapilloCheck(®). The agreement between both methods was 69.4% for HPV 16; 79.1% for HPV 45; 82.4% for HPV 18; 93.6% for HPV 31; 87.9% for HPV 33, and 17.6% for HPV 39. The assay had higher sensitivity than the Papillocheck(®), particularly for identifying HPV 16 and 18. The MCHA seemed to be sensitive and specific for the identification of the most prevalent HPV types in invasive cervical cancer, HPV 16, 18, 45, 33 and 31. It requires low-cost reagents and common laboratory apparatus.

Collaboration


Dive into the Rosa Dea Sperhacke's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arnaldo Zaha

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Marta Osório Ribeiro

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Afrânio Lineu Kritski

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Luciene Cardoso Scherer

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Patrícia Izquierdo Cafrune

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Franciele Rosso

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Marcus Barreto Conde

Federal University of Rio de Janeiro

View shared research outputs
Researchain Logo
Decentralizing Knowledge